死亡风险显著降低34%,广东新药有望定义全球癌症治疗的金标准

21世纪经济报道
Jun 01

北京时间5月31日,在2026年美国临床肿瘤学会(ASCO)年会上,康方生物自主研发的全球首创PD-1/VEGF双特异性抗体依沃西新药研究(HARMONi-6研究)成果发布。该新药使得肺鳞癌患者的死亡风险降低34%,同时HARMONi-6研究也是ASCO成立61年来,首个进入全体大会的中国原创新药研究,这意味着中国创新药有能力重新定义全球癌症治疗的金标准。  肺鳞癌长期以来治疗手段匮乏,患者预后...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10